Bausch is keen on Syn­er­gy, af­ter trou­bled con­sti­pa­tion drug mak­er files for Chap­ter 11

Syn­er­gy Phar­ma­ceu­ti­cals $SGYP has filed for bank­rupt­cy, cap­ping a mis­er­able year for the con­sti­pa­tion drug mak­er which in Oc­to­ber sug­gest­ed it did not an­tic­i­pate re­ceiv­ing any takeover of­fers, de­spite dis­play­ing a for-sale sign for months. On Wednes­day, Bausch Health $BHC — for­mer­ly Valeant — emerged from the shad­ows, with a stalk­ing horse bid for the bulk of Syn­er­gy’s as­sets for a cool $200 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER